CELGENE CORPORATION (CELG)

+Follow

Open and Closed Open Only Closed Only ?

Analyst ?	Research Firm ?	Signal ?	Signal Date ?	Initial Price ?	Price Target ?	Closing Date ?	Return ?
Charles Graham	Unaffiliated	Buy	Feb 14, '14		210.00	Feb 14, '15	N/A
Jim Birchenough	BMO Capital Markets	Buy	Jan 31, '14	151.93	211.00	Jan 31, '15	8.43%
Robyn Karnauskas	Deutsche Bank Securities	Buy	Jan 28, '14	159.98	190.00	Jan 28, '15	2.98%
Ying Huang	Barclays	Buy	Jan 10, '14	169.81	182.00	Jan 10, '15	-2.99%
Ian Somaiya	Piper Jaffray	Buy	Jan 08, '14	167.46		Jan 08, '15	-1.62%
Matt Roden	UBS	Sell	Jan 07, '14	164.61		Jan 07, '15	-0.08%
Matt Roden	UBS	Buy	Dec 05, '13	164.51	200.00	Dec 05, '14	0.14%
Jim Birchenough	BMO Capital Markets	Buy	Oct 25, '13	155.74	200.00	Oct 25, '14	5.78%
Ying Huang	Barclays	Buy	Oct 25, '13	155.74	173.00	Oct 25, '14	5.78%
Gene Mack	Brean Murray, Carret & Co.	Buy	Oct 25, '13	155.74		Oct 25, '14	5.78%
Thomas Wei	Jefferies & Co.	Buy	Oct 25, '13	155.74	185.00	Oct 25, '14	5.78%
Robyn Karnauskas	Deutsche Bank Securities	Buy	Oct 24, '13	157.96	170.00	Oct 24, '14	7.62%
Bret Holley	Guggenheim Securities LLC	Buy	Oct 24, '13	157.96	176.00	Oct 24, '14	4.29%
Michael Yee	RBC Capital Markets	Buy	Oct 09, '13	146.87	170.00	Oct 09, '14	15.75%
Howard Liang	Leerink Swann Llc	Buy	Sep 25, '13	145.56	177.00	Sep 25, '14	13.18%
Thomas Wei	Jefferies & Co.	Buy	Jul 26, '13	143.94	161.00	Jul 26, '14	14.45%
Jim Birchenough	BMO Capital Markets	Buy	Jul 26, '13	143.94	180.00	Jul 26, '14	14.45%
John Eade	Argus Research Company	Buy	Jun 12, '13	118.11	140.00	Jun 12, '14	39.48%
Mara Goldstein	Cantor Fitzgerald	Buy	Apr 21, '13	126.84	142.00	Apr 21, '14	29.88%
Thomas Wei	Jefferies & Co.	Buy	Apr 11, '13	122.99		Apr 11, '14	33.95%

See more news releases in Medical Pharmaceuticals

Ritalin (R) LA, a New Once-Daily Treatment for ADHD, Receives FDA Approvable Letter

    EAST HANOVER, N.J., and WARREN, N.J., Oct. 2 /PRNewswire/ --
 Novartis Pharmaceuticals Corporation and Celgene Corporation announced today
 that they received an approvable letter from the U.S. Food and Drug
 Administration (FDA) for Ritalin (R) LA (methylphenidate HCl extended-release
 capsules) for the treatment of Attention Deficit/Hyperactivity Disorder
 (ADHD).  Ritalin LA is a new, once-daily formulation of Ritalin (R)
 (methylphenidate HCl), which eliminates the need for a mid-day dose during
 school.
     An approvable letter usually represents the final step before a product
 receives FDA clearance for marketing in the United States.  Ritalin LA is part
 of a broad partnering agreement between Novartis and Celgene Corporation
 (Nasdaq:   CELG) encompassing the entire Ritalin product line.  Novartis
 licensed intellectual property rights related to the formulation of Ritalin LA
 from Celgene.
     "Novartis is very pleased that the FDA has issued an approvable letter for
 Ritalin LA and will work closely with the agency to finalize approval and make
 it available in the United States," said Larry Perlow, M.D., Senior Vice
 President and General Manager, Commercial Operations, Novartis Pharmaceuticals
 Corporation.  "Ritalin LA represents an important advance in ADHD treatment.
 It will offer physicians, patients and parents a new once-a-day option with
 the known safety and efficacy of Ritalin, a product that has helped
 generations of people with ADHD.  Ritalin LA will be taken once daily, which
 will eliminate the need for children to take their medication during the
 school day."
     Novartis submitted a new drug application (NDA) to the FDA on November 29,
 2000. Ritalin LA was shown to significantly improve ADHD symptoms.  Overall,
 Ritalin LA was considered effective, safe and well tolerated in clinical
 trials involving children aged 6 to 12 years.
     "Ritalin LA will offer physicians more flexibility in treating children
 with ADD and ADHD," said Sol J. Barer, Ph.D., President and Chief Operating
 Officer, Celgene Corporation.
     ADHD is a neurobiologic disorder that interferes with an individual's
 ability to regulate activity level and behavior, and sustain focus in ways
 appropriate to his or her age.  ADHD is the most studied childhood psychiatric
 disorder and is supported by a substantial body of scientific evidence.
 Scientific research indicates that ADHD may be related to deficiencies in
 certain neurotransmitters in the brain.  Novartis supports only the proper
 diagnosis and treatment of ADHD.
     Ritalin LA will join the Novartis ADHD product portfolio, which includes
 Ritalin, Ritalin SR (methylphenidate HCl sustained-release tablets), and
 dexmethylphenidate HCl, a refined formulation of Ritalin.  Novartis licensed
 the worldwide (excluding Canada) marketing and development rights to
 dexmethylphenidate HCl from Celgene Corporation.
     Novartis Pharmaceuticals Corporation researches, develops, manufactures
 and markets leading innovative prescription drugs used to treat a number of
 diseases and conditions, including central nervous system disorders, organ
 transplantation, cardiovascular diseases, dermatological diseases, respiratory
 disorders, cancer and arthritis.  The company's mission is to improve people's
 lives by pioneering novel healthcare solutions.
     The Novartis Group (NYSE:   NVS) is a world leader in healthcare with core
 businesses in pharmaceuticals, consumer health, generics, eye-care, and animal
 health.  In 2000, the Group's ongoing businesses achieved sales of CHF 29.1
 billion (USD 17.2 billion) and a net income of CHF 6.5 billion (USD 3.9
 billion).  The Group invested approximately CHF 4.0 billion (USD 2.4 billion)
 in R&D.  Headquartered in Basel, Switzerland, Novartis employs about 70,000
 people and operates in over 140 countries around the world.   For further
 information please consult http://www.novartis.com.
     Celgene Corporation, located in Warren, New Jersey, is an independent
 biopharmaceutical company engaged primarily in the discovery, development and
 commercialization of orally administered, small molecule drugs for the
 treatment of cancer and inflammatory diseases through gene regulation.  Please
 feel free to visit the Company's web site at http://www.celgene.com.
 
     The foregoing press release contains forward-looking statements that can
 be identified by forward looking terminology such as "will", "may", "look
 forward to making this new product available", "look forward to working
 closely", "should", "can" or similar expressions. Such forward looking
 statements involve known and unknown risks, uncertainties and other factors
 that may cause the actual results to be materially different from any future
 results, performance, or achievements expressed or implied by such statements.
 In particular, management's expectation regarding the commercialization of
 Ritalin LA could be affected by amongst other things, uncertainties relating
 to product development, regulatory actions or delays or government regulation
 generally, the ability to obtain or maintain patent or other proprietary
 intellectual property protection and competition in general, as well as
 factors discussed in the Company's Form 20F filed with the Securities and
 Exchange Commission. Should one or more of these risks or uncertainties
 materialise, or should underlying assumptions prove incorrect, actual results
 may vary materially from those described herein anticipated, believed,
 estimated or expected.
 
      Contact:
 
      Regina Moran
      Novartis Pharmaceuticals Corporation
      973-781-5567
      regina.moran@pharma.novartis.com
 
      Denise Brashear
      Novartis Pharmaceuticals Corporation
      973-781-7336
      denise.brashear@pharma.novartis.com
 
      - OR -
 
      Robert J. Hugin
      Celgene Corporation
      (732) 271-4102
      rhugin@celgene.com
 
      Todd Ringler
      Feinstein Kean Healthcare
      617-761-6791
      tringler@fkhealth.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X59280500
 
 

SOURCE  Novartis Pharmaceuticals Corporation